Close Menu

Europe

The US DOJ alleged that the company conspired to "artificially delay" ordering its MammaPrint test in order to circumvent Medicare's 14-day rule.

Researchers found that diurnal gut microbe fluctuations are disrupted in individuals with type 2 diabetes, leading to a bacterial signature for risk profiling.

The software tool, currently in development, is set to be introduced next year and could also find application in other indications such as cancer.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

News items for the week of June 29, 2020.

Earlier this month Centogene said that previously acquired laboratory space in Hamburg is now exclusively performing SARS-CoV-2 testing.

In Genome Research this week: Y chromosome gene expression analysis, de novo mutations rise with paternal age in rhesus macaques, and more.

The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease. 

RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.

In PNAS this week: effect of premature termination codons in the DMD gene, knock-down of DUX4 in facioscapulohumeral muscular dystrophy, and more.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.